Get the Stockscreener App
7.89
4.11%
-0.38
Immunitybio Inc stock is traded at $7.89, with a volume of 9.55M.
It is down -4.11% in the last 24 hours and up +19.79% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.27
Open:
$8.13
24h Volume:
9.55M
Relative Volume:
0.28
Market Cap:
$8.13B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-20.24
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-11.50%
1M Performance:
+19.79%
6M Performance:
+205.00%
1Y Performance:
+176.30%
1-Day Range:
$7.82
$8.23
1-Week Range:
$7.77
$9.12
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.905 | 8.50B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.94 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.71 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.11 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.00 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Assessing ImmunityBio (IBRX) Valuation After FDA Acknowledges Resubmitted ANKTIVA Bladder Cancer Filing - simplywall.st
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.2%What's Next? - MarketBeat
Immunitybio stock initiated at Buy by BTIG with $13 target - Investing.com
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst - Stocktwits
IBRX Stock Falls -23% In 6-Day Spree On Profit-Taking After 500% YTD Gain - Trefis
ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn - TipRanks
ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation - timothysykes.com
ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - marketscreener.com
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge - simplywall.st
FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story - Yahoo Finance
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) - Finviz
ImmunityBio (NASDAQ:IBRX) Shares Down 2.5%Should You Sell? - MarketBeat
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Bitget
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data - The Malaysian Reserve
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Asianet Newsable
ImmunityBio Stock Sinks as FDA Review Drags On - TipRanks
ImmunityBio resubmits bladder cancer application to FDA - Investing.com
ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG - TipRanks
FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits
ImmunityBio’s Stock Sees a Huge Boost - Los Angeles Business Journal
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
How dovish Fed policy supports ImmunityBio Inc. (26CA) stock2026 Technicals & Weekly Market Pulse Alerts - Naître et grandir
ImmunityBio (IBRX) soars to new high on Anktiva future expansion - MSN
Vanguard Group Inc. Boosts Stock Position in ImmunityBio, Inc. $IBRX - MarketBeat
How ImmunityBio Inc. stock valuations compare to rivalsJuly 2025 Drop Watch & Fast Entry High Yield Tips - Naître et grandir
Rafferty Asset Management LLC Grows Stake in ImmunityBio, Inc. $IBRX - MarketBeat
ImmunityBio (NASDAQ:IBRX) Trading Down 3.2%Time to Sell? - MarketBeat
H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating - Bitget
ImmunityBio ANKTIVA Milestones Reshape Growth Outlook And Risk Profile - Sahm
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions - Stocktwits
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies - Yahoo Finance
ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout - Yahoo Finance
ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses - Yahoo Finance
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Piper Sandler Maintains Overweight on ImmunityBio (IBRX) March 2026 - Meyka
ImmunityBio Shares Retreat Despite Strong Commercial Momentum - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Stock Price Down 10.2%What's Next? - MarketBeat
ImmunityBio Director’s Share Sale Spurs Investigations: Stock Faces Downturn - timothysykes.com
IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth - The Chronicle-Journal
ImmunityBio (NASDAQ:IBRX) Shares Gap DownTime to Sell? - MarketBeat
Major Director Share Sale Hits ImmunityBio Stock - StocksToTrade
ImmunityBio (IBRX) Shares Drop Nearly 10% as Investors Digest Recent Earnings - International Business Times Australia
ImmunityBio Faces Increased Investor Skepticism Amid Recent Developments - timothysykes.com
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):